Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

An epidermal inclusion cyst is a benign lesion, frequently observed throughout the body. However, its presence in the retrorectal region is a rare occurrence. With a higher incidence in women and non-specific symptoms, these cysts are mostly an incidental finding. Here, we report a case of a 33-year-old female presenting with complaints of abdominal pain and sensation of incomplete and painful defecation. The patient's history revealed that a large pelvic cyst was found incidentally during her first cesarean section (CS) owing to an arrest in labor. A presumptive diagnosis of rectal duplication cyst was made based on digital rectal exam (DRE), computed tomography (CT), and magnetic resonance imaging (MRI) findings. For cyst removal, the patient underwent a midline laparotomy. A postoperative biopsy led to the confirmed diagnosis of the retrorectal epidermal inclusion cyst. On follow-up, our patient showed a smooth recovery without any complications. We conclude that when dealing with a pregnant woman with a pelvic mass, developmental cysts should always be kept in mind. Timely diagnosis and management of a retrorectal mass is essential for effective treatment and to prevent subsequent complications.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710341PMC
http://dx.doi.org/10.7759/cureus.11300DOI Listing

Publication Analysis

Top Keywords

epidermal inclusion
12
inclusion cyst
12
retrorectal epidermal
8
incidental finding
8
cyst
6
retrorectal
4
cyst incidental
4
finding cesarean
4
cesarean epidermal
4
cyst benign
4

Similar Publications

Clitoral cyst is an epidermal inclusion cyst that results from invagination of the epidermis into the dermis or subcutaneous tissue. It commonly occurs following trauma from female genital mutilation (FGM), with presentation typically in childhood or the peripubertal period. Later, presentations often arise due to the asymptomatic nature of the condition and the associated stigma.

View Article and Find Full Text PDF

Purpose: Combinatorial therapies are essential for treating advanced non-small cell lung cancer (NSCLC), particularly overcoming resistance to third-generation epidermal growth factor receptor (EGFR) like osimertinib (OSI). The Hippo signaling pathway, a critical regulator of cell proliferation, apoptosis, and tumor progression, is often dysregulated in NSCLC and contributes to chemo-resistance. This study investigated the potential of epigallocatechin-3-gallate (EGCG), a green tea polyphenol, to overcome OSI resistance by modulating the Hippo signaling pathway, specifically through inhibition of the YAP-1 (Yes-associated protein)-TEAD (TEA domain transcription factor)-CTGF (connective tissue growth factor) axis.

View Article and Find Full Text PDF

Follicular unit extraction (FUE) has become a leading technique in hair transplantation, yet optimal management of the donor area remains a clinical challenge. This systematic review analyzes intraoperative and postoperative interventions applied to the donor area in FUE hair transplantation, with a focus on both clinical outcomes and the cellular and molecular mechanisms involved in tissue repair, inflammatory response, and regenerative processes. A comprehensive literature search was conducted in PubMed and EMBASE (January 2000-June 2025), identifying clinical studies that evaluated donor area treatments and reported outcomes related to healing, inflammation, infection, and patient satisfaction.

View Article and Find Full Text PDF

Background: In advanced non-small cell lung cancer with EGFR mutations, third-generation EGFR TKIs (3-G TKIs) are currently the preferred first-line treatment. Previous studies have demonstrated that combining first-generation EGFR TKIs with chemotherapy (1-G TKIs + chemo) also significantly enhances efficacy compared to 1-G TKIs alone. This study aims to compare the effectiveness of 1-G TKIs + chemo against 3-G TKIs.

View Article and Find Full Text PDF

Capivasertib cost-effectiveness in treating advanced breast cancer: A US health care perspective.

J Manag Care Spec Pharm

September 2025

Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, TX.

Background: Capivasertib has gained US Food and Drug Administration approval in combination with a hormonal-based regimen (eg, fulvestrant) for managing hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, with results from the CapiTello-291 trial showing Capivasertib plus fulvestrant to have superior efficacy compared with fulvestrant alone.

Objective: To examine the cost-effectiveness of capivasertib plus fulvestrant vs fulvestrant alone for treating HR+/HER2- advanced breast cancer in the United States from a payer's perspective.

Methods: A Markov model of 708 participants with 3 health states (progression-free, progressive disease, death) from CapiTello-291 trial data was used to compare the costs and efficacy of the two treatment strategies on TreeAge Pro software.

View Article and Find Full Text PDF